The EVPChief Commercial Officer of Vertex Pharmaceuticals (VRTX) is Buying Shares

Today, the EVPChief Commercial Officer of Vertex Pharmaceuticals (VRTX), Stuart Arbuckle, bought shares of VRTX for $280.3K.

Following this transaction Stuart Arbuckle’s holding in the company was increased by 4.53% to a total of $8.62 million. In addition to Stuart Arbuckle, 4 other VRTX executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Vertex Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $783 million and quarterly net profit of $129 million. In comparison, last year the company earned revenue of $578 million and had a GAAP net loss of $103 million. VRTX’s market cap is $47B and the company has a P/E ratio of 73.55. Currently, Vertex Pharmaceuticals has an average volume of 1.03M.

Starting in October 2018, VRTX received 12 Buy ratings in a row. 11 different firms, including Cantor Fitzgerald and Raymond James, currently also have a Buy rating on the stock. Based on 12 analyst ratings, the analyst consensus is Strong Buy with an average price target of $206.55, reflecting a 14.6% upside.

The insider sentiment on Vertex Pharmaceuticals has been positive according to 120 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Stuart Arbuckle’s trades have generated a 5.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Read More on VRTX: